CellaVision AB (publ)
CLVSFOTCHealthcare● Active
$13.49
+$0.00(+0.00%)
Market Cap$321757369
P/E Ratio—
52W High$19.2796
52W Low$13.49
CellaVision AB (publ) (CLVSF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLVSF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 24, 2026EPS Actual
$0.10
Est. $0.16 · -40.4%
Revenue
$0.02B
Est. $0.02B · -12.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 24, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CLVSF reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 16, 2026 | $0.15 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | Apr 24, 2026 | $0.16 | $0.10 | -40.4% | $0.02B | $0.02B | -12.6% |
| ▲ Q1 FY2026 | Feb 5, 2026 | $0.14 | $0.19 | +37.3% | $0.02B | $0.02B | +2.7% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.11 | $0.14 | +24.4% | $0.02B | $0.02B | -0.6% |
| ▼ Q3 FY2025 | Jul 17, 2025 | $0.17 | $0.16 | -4.8% | $0.02B | $0.02B | +3.3% |
| ▲ Q2 FY2025 | May 2, 2025 | $0.14 | $0.17 | +26.9% | $0.02B | $0.02B | +4.5% |
| ▼ Q1 FY2025 | Feb 6, 2025 | $0.17 | $0.15 | -9.1% | $0.02B | $0.02B | -7.8% |
| ▼ Q4 FY2024 | Oct 24, 2024 | $0.17 | $0.13 | -22.3% | $0.02B | $0.02B | -3.9% |
Q3 FY2026
Jul 16, 2026
EPS Actual
—
EPS Est.
$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 24, 2026Miss
EPS Actual
$0.10
EPS Est.
$0.16
EPS Surpr.
-40.4%
Revenue
$0.02B
Q1 FY2026
Feb 5, 2026Beat
EPS Actual
$0.19
EPS Est.
$0.14
EPS Surpr.
+37.3%
Revenue
$0.02B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.14
EPS Est.
$0.11
EPS Surpr.
+24.4%
Revenue
$0.02B
Q3 FY2025
Jul 17, 2025Miss
EPS Actual
$0.16
EPS Est.
$0.17
EPS Surpr.
-4.8%
Revenue
$0.02B
Q2 FY2025
May 2, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.14
EPS Surpr.
+26.9%
Revenue
$0.02B
Q1 FY2025
Feb 6, 2025Miss
EPS Actual
$0.15
EPS Est.
$0.17
EPS Surpr.
-9.1%
Revenue
$0.02B
Q4 FY2024
Oct 24, 2024Miss
EPS Actual
$0.13
EPS Est.
$0.17
EPS Surpr.
-22.3%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $1.87 | $2.02 | $2.15 | 1 |
| Q3 FY2026 | $1.48 | $1.60 | $1.70 | 1 |
| Q2 FY2026 | $1.31 | $1.41 | $1.50 | 1 |
| Q1 FY2026 | $1.43 | $1.54 | $1.64 | 1 |
| Q4 FY2025 | $1.30 | $1.31 | $1.32 | 1 |
| Q3 FY2025 | $0.98 | $1.06 | $1.13 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
| Q2 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
| Q1 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2025 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2025 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 24, 2026 | -40.4% | $16.14 | $13.49 | -16.42% |
| ▲ Q1 FY2026 | Feb 5, 2026 | +37.3% | $15.45 | $15.85 | +2.59% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +24.4% | $19.28 | $19.28 | +0.00% |
| ▼ Q3 FY2025 | Jul 17, 2025 | -4.8% | $19.28 | $19.28 | +0.00% |
| ▲ Q2 FY2025 | May 2, 2025 | +26.9% | $19.28 | $19.28 | +0.00% |
| ▼ Q1 FY2025 | Feb 6, 2025 | -9.1% | $19.28 | $19.28 | +0.00% |
| ▼ Q4 FY2024 | Oct 24, 2024 | -22.3% | $25.91 | $25.91 | +0.00% |
| ▼ Q3 FY2024 | Jul 19, 2024 | -4.8% | $20.24 | $24.21 | +19.61% |
Q2 FY2026-16.42%
Report Date
Apr 24, 2026
EPS Beat/Miss
-40.4%
Price Before
$16.14
Price After
$13.49
Q1 FY2026+2.59%
Report Date
Feb 5, 2026
EPS Beat/Miss
+37.3%
Price Before
$15.45
Price After
$15.85
Q4 FY2025+0.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
+24.4%
Price Before
$19.28
Price After
$19.28
Q3 FY2025+0.00%
Report Date
Jul 17, 2025
EPS Beat/Miss
-4.8%
Price Before
$19.28
Price After
$19.28
Q2 FY2025+0.00%
Report Date
May 2, 2025
EPS Beat/Miss
+26.9%
Price Before
$19.28
Price After
$19.28
Q1 FY2025+0.00%
Report Date
Feb 6, 2025
EPS Beat/Miss
-9.1%
Price Before
$19.28
Price After
$19.28
Q4 FY2024+0.00%
Report Date
Oct 24, 2024
EPS Beat/Miss
-22.3%
Price Before
$25.91
Price After
$25.91
Q3 FY2024+19.61%
Report Date
Jul 19, 2024
EPS Beat/Miss
-4.8%
Price Before
$20.24
Price After
$24.21
Avg Beat Reaction+0.86%
Avg Miss Reaction+0.64%
Beat Rate3 / 8 quarters
Largest Move+19.61% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLVSF ends December
CellaVision AB (publ) (CLVSF) most recently reported earnings on April 24, 2026 for Q2 FY2026, posting EPS of $0.10 — missing the analyst consensus of $0.16 by -40.4%. The next CLVSF earnings date is expected around September 1, 2026.
Each quarter, investors track CLVSF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLVSF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLVSF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLVSF earnings · 5 questionsCellaVision AB (publ)'s next earnings report is expected around September 1, 2026. CLVSF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLVSF historically reports after market close (AMC).
CLVSF earnings datewhen is CLVSF earningsCLVSF next earnings datewhen does CLVSF report earningsCLVSF earnings calendar
▸ Source: FMP · CellaVision AB (publ) SEC filings · US GAAP · CellaVision AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026